ATE443719T1 - Interleukin-18 bindende proteine, deren herstellung und verwendung - Google Patents

Interleukin-18 bindende proteine, deren herstellung und verwendung

Info

Publication number
ATE443719T1
ATE443719T1 AT98938877T AT98938877T ATE443719T1 AT E443719 T1 ATE443719 T1 AT E443719T1 AT 98938877 T AT98938877 T AT 98938877T AT 98938877 T AT98938877 T AT 98938877T AT E443719 T1 ATE443719 T1 AT E443719T1
Authority
AT
Austria
Prior art keywords
interleukin
production
binding proteins
proteins
binding
Prior art date
Application number
AT98938877T
Other languages
German (de)
English (en)
Inventor
Daniela Novick
Charles Dinarello
Menachem Rubinstein
Soo Kim
Original Assignee
Yeda Res & Dev
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from IL12155497A external-priority patent/IL121554A0/xx
Priority claimed from IL12163997A external-priority patent/IL121639A0/xx
Application filed by Yeda Res & Dev filed Critical Yeda Res & Dev
Application granted granted Critical
Publication of ATE443719T1 publication Critical patent/ATE443719T1/de

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C07K14/7155Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for interleukins [IL]
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52Cytokines; Lymphokines; Interferons
    • C07K14/54Interleukins [IL]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/06Antipsoriatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/06Immunosuppressants, e.g. drugs for graft rejection
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10STECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/82Proteins from microorganisms
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10STECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/82Proteins from microorganisms
    • Y10S530/826Viruses
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10STECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/827Proteins from mammals or birds
    • Y10S530/834Urine; urinary system

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Diabetes (AREA)
  • Cell Biology (AREA)
  • Transplantation (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Neurosurgery (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Biomedical Technology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Dermatology (AREA)
  • Endocrinology (AREA)
  • Neurology (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
AT98938877T 1997-08-14 1998-08-13 Interleukin-18 bindende proteine, deren herstellung und verwendung ATE443719T1 (de)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
IL12155497A IL121554A0 (en) 1997-08-14 1997-08-14 Interleukin-18 binding proteins their preparation and use
IL12163997A IL121639A0 (en) 1997-08-14 1997-08-27 Interleukin-18 binding proteins their preparation and use
IL12186097A IL121860A0 (en) 1997-08-14 1997-09-29 Interleukin-18 binding proteins their preparation and use
IL12213497A IL122134A0 (en) 1997-08-14 1997-11-06 Interleukin-18 binding proteins their preparation and use
IL12546398A IL125463A0 (en) 1997-08-14 1998-07-22 Interleukin-18 binding proteins their preparation and use
PCT/IL1998/000379 WO1999009063A1 (en) 1997-08-14 1998-08-13 Interleukin-18 binding proteins, their preparation and use

Publications (1)

Publication Number Publication Date
ATE443719T1 true ATE443719T1 (de) 2009-10-15

Family

ID=27517687

Family Applications (1)

Application Number Title Priority Date Filing Date
AT98938877T ATE443719T1 (de) 1997-08-14 1998-08-13 Interleukin-18 bindende proteine, deren herstellung und verwendung

Country Status (28)

Country Link
US (4) US6605280B1 (en:Method)
EP (1) EP1003781B1 (en:Method)
JP (1) JP4272348B2 (en:Method)
KR (1) KR100687388B1 (en:Method)
CN (1) CN1243021C (en:Method)
AR (2) AR013422A1 (en:Method)
AT (1) ATE443719T1 (en:Method)
AU (1) AU755794B2 (en:Method)
BG (1) BG65519B1 (en:Method)
BR (1) BRPI9811940B8 (en:Method)
CA (1) CA2298855C (en:Method)
CY (1) CY1109664T1 (en:Method)
CZ (1) CZ300818B6 (en:Method)
DE (2) DE69841175D1 (en:Method)
DK (1) DK1003781T3 (en:Method)
EA (1) EA003675B1 (en:Method)
EE (1) EE05538B1 (en:Method)
ES (1) ES2149149T3 (en:Method)
HU (1) HU226698B1 (en:Method)
IL (5) IL121860A0 (en:Method)
NO (1) NO327240B1 (en:Method)
NZ (1) NZ502392A (en:Method)
PL (1) PL206070B1 (en:Method)
PT (1) PT1003781E (en:Method)
SI (1) SI1003781T1 (en:Method)
SK (1) SK287194B6 (en:Method)
UA (1) UA75862C2 (en:Method)
WO (1) WO1999009063A1 (en:Method)

Families Citing this family (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7393663B2 (en) * 1997-08-01 2008-07-01 Serono Genetics Institute S.A. Expressed sequence tags and encoded human proteins
IL121860A0 (en) * 1997-08-14 1998-02-22 Yeda Res & Dev Interleukin-18 binding proteins their preparation and use
CA2276216A1 (en) * 1998-06-24 1999-12-24 Kabushiki Kaisha Hayashibara Seibutsu Kagaku Kenkyujo An artificial peptide capable of neutralizing the biological activity of interleukin-18
WO2000012555A1 (en) * 1998-09-01 2000-03-09 Kabushiki Kaisha Hayashibara Seibutsu Kagaku Kenkyujo Interleukin 18-binding protein
AR022952A1 (es) 1999-03-19 2002-09-04 Smithkline Beecham Corp ANTICUERPO MONOCLONAL DE ROEDOR ESPECIFICAMENTE NEUTRALIZANTE PARA LA INTERLEUQUINA-18 HUMANA , UN FRAGMENTO FAB NEUTRALIZANTE o FRAGMENTO F(AB')2, UNA REGION DE COMPLEMENTARIEDAD DE CADENA LIGERA DE INMONOGLOBULINA(CDR), UNA MOLECULA DE ACIDO NUCLEICO, COMPOSICION FARMACEUTICA QUE LO COMPRENDE, EL
IL131047A0 (en) * 1999-07-22 2001-01-28 Yeda Res & Dev Use of il-18 inhibitors
CA2324168A1 (en) * 1999-11-16 2001-05-16 Kabushiki Kaisha Hayashibara Seibutsu Kagaku Kenkyujo Antibody specific to interleukin 18 precursor
EP2338515A3 (en) * 2000-02-10 2011-11-16 Abbott Laboratories Antibodies that bind human interleukin-18 and methods of making and using
CA2683009C (en) * 2000-02-21 2014-09-23 Applied Research Systems Ars Holding N.V. Use of il-18 inhibitors
AU2005211606B2 (en) * 2000-05-05 2007-02-22 Inserm - Institut National De La Sante Et De La Recherche Medicale Use of IL-18 inhibitors for the treatment and/or prevention of atherosclerosis
HU229375B1 (en) * 2000-05-05 2013-11-28 Inst Nat Sante Rech Med Use of il-18 inhibitors for the treatment and/or prevention of atherosclerosis
WO2002031115A2 (en) * 2000-10-11 2002-04-18 Viron Therapeutics, Inc. Nucleic acid molecules and polypeptides for immune modulation
US7718368B2 (en) * 2000-12-04 2010-05-18 Viron Therapeutics Inc. Immunomodulatory protein and useful embodiments thereof
ME00549B (me) * 2001-01-29 2011-10-10 Serono Lab Upotreba inhibitora il-18 za liječenje i/ili prevenciju srčanih oboljenja
JP4502580B2 (ja) * 2001-05-16 2010-07-14 イエダ リサーチ アンド ディベロップメント カンパニー リミテッド 敗血症の治療または予防のためのil−18阻害剤の使用
EP1390070B1 (en) * 2001-05-25 2017-02-08 Ares Trading S.A. Use of il-18 inhibitors for treating or preventing cns injuries
PT2087908T (pt) 2001-06-26 2018-07-16 Amgen Inc Anticorpos contra opgl
UA78516C2 (en) * 2001-08-10 2007-04-10 Applied Research Systems Use of inhibitors of il-18 for treatment and/or prevention of hypersensitivity disorders, and in particular of delayed-type hypersensitivity
HRP20040758B1 (hr) * 2002-03-22 2012-10-31 Institut National de la Santé et de la Recherche Médicale Uporaba il-18 inhibitora za lijeäśenje i/ili prevenciju perifernih krvožilnih bolesti
US20040136992A1 (en) 2002-08-28 2004-07-15 Burton Paul B. J. Compositions and method for treating cardiovascular disease
WO2004032837A2 (en) * 2002-10-08 2004-04-22 Ares Trading S.A. The use of cytokine able to bind il-18bp and of inhibiting the activity of a second cytokine
IL152232A0 (en) 2002-10-10 2003-05-29 Yeda Res & Dev Promoter to il-18bp, its preparation and use
US7491803B2 (en) 2003-04-30 2009-02-17 Japan Science & Technology Agency Human anti-human interleukin-18 antibody, fragment thereof and method for using same
HRP20120246T1 (hr) 2003-05-13 2012-04-30 Merck Serono Sa Aktivne varijante il-18 vezujućeg proteina i njihove medicinske upotrebe
PL1689777T3 (pl) * 2003-11-05 2007-09-28 Ares Trading Sa Sposób oczyszczania białka wiążącego IL-18
JP4979385B2 (ja) 2003-11-12 2012-07-18 ザ・リージエンツ・オブ・ザ・ユニバーシテイ・オブ・コロラド、ア・ボデイー・コーポレイト 腫瘍壊死因子αの調節のための組成物及び方法
US20050100965A1 (en) * 2003-11-12 2005-05-12 Tariq Ghayur IL-18 binding proteins
US7968684B2 (en) 2003-11-12 2011-06-28 Abbott Laboratories IL-18 binding proteins
IL159670A0 (en) * 2003-12-31 2004-06-01 Yeda Res & Dev Use of il-18 binding protein in inflammations
PL1720979T3 (pl) * 2004-03-01 2008-03-31 Ares Trading Sa Zastosowanie podłoża pozbawionego surowicy do hodowli komórkowej do wytwarzania IL-18BP w komórkach ssaków
US7557084B2 (en) * 2004-03-31 2009-07-07 Regeneron Pharmaceuticals, Inc. IL-18 specific polypeptides and therapeutic uses thereof
JP5043654B2 (ja) * 2004-06-29 2012-10-10 アレス トレーディング ソシエテ アノニム Il−18結合タンパク質の精製のための方法
DK1888100T3 (da) 2005-06-03 2012-01-23 Merck Serono Sa Anvendelse af IL-18BP-isoformer til behandling og/eller forebyggelse af neurologiske inflammatoriske sygdomme
PL1885753T3 (pl) * 2005-06-03 2011-12-30 Ares Trading Sa Wytwarzanie rekombinowanego białka wiążącego IL-18
ATE529433T1 (de) * 2005-06-10 2011-11-15 Ares Trading Sa Verfahren zur reinigung eines il-18-bindenden proteins
CN101003812B (zh) * 2006-01-17 2011-01-05 温州医学院 一种用于制备重组人egf-il18融合蛋白的方法
AU2007267213B2 (en) 2006-05-25 2012-03-29 Glaxo Group Limited Modified humanised anti-interleukin-18 antibodies
WO2010040736A2 (en) * 2008-10-07 2010-04-15 Ablynx Nv Amino acid sequences directed against il18 and/or the il-18 receptor and polypeptides comprising the same for the treatment of diseases and/or disorders associated with il-18 mediated signaling
US20150352561A1 (en) * 2013-01-02 2015-12-10 Wilsa Holdings ,LLC Method and Apparatus for Conditioning Fluids
PH12016500425B1 (en) * 2013-09-05 2022-07-29 Ab2 Bio Sa Il-18 binding protein (il-18bp) in inflammatory diseases
CA2972689A1 (en) 2015-03-05 2016-09-09 Ab2 Bio Sa Il-18 binding protein (il-18bp) and antibodies in inflammatory diseases
EP3943097A1 (en) 2020-07-24 2022-01-26 AB2 Bio SA Car-t cell therapy
CN120737196A (zh) * 2022-01-28 2025-10-03 和径医药科技(上海)有限公司 一种靶向il-18bp的抗体及其应用
KR20240144422A (ko) * 2022-03-15 2024-10-02 컴퓨젠 엘티디. 암 치료의 단독치료법 및 병용치료법에서 il-18bp 길항제 항체 및 이의 용도
CN114605521A (zh) * 2022-04-06 2022-06-10 内蒙古农业大学 一种细胞免疫调节蛋白及其应用
CN114891125B (zh) * 2022-06-16 2023-04-11 广东医科大学 一种长效重组白细胞介素-18结合蛋白及其生产方法与应用
CN120530131A (zh) 2023-01-06 2025-08-22 拉森医疗公司 抗il-18bp抗体
TW202515608A (zh) 2023-06-26 2025-04-16 以色列商坎布根有限公司 Il—18bp拮抗抗體及其於癌症治療之單一療法及組合療法的用途

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5985863A (en) 1996-09-12 1999-11-16 Vertex Pharmaceuticals, Inc. Compositions and methods for decreasing IGIF and IFN-γ production by administering an ICE inhibitor
GB9214857D0 (en) * 1992-07-13 1992-08-26 Medical Res Council Human nucleic acid fragments and their use
US5744451A (en) 1995-09-12 1998-04-28 Warner-Lambert Company N-substituted glutamic acid derivatives with interleukin-1 β converting enzyme inhibitory activity
US5776731A (en) 1996-02-21 1998-07-07 Immunex Corporation DNA encoding type-I interleukin-I receptor-like protein designated 2F1
PT936923E (pt) 1996-11-15 2004-04-30 Kennedy Inst Of Rheumatology Supressao de tnfalfa e il-12 em terapia
ATE346085T1 (de) 1996-12-06 2006-12-15 Vertex Pharma Inhibitoren des interleukin-1-beta konvertierenden enzyms
US7141393B2 (en) 1996-12-26 2006-11-28 Kabushiki Kaisha Hayashibara Seibutsu Kagaku Kenkyujo Interleukin-18-receptor proteins
US6087116A (en) 1997-03-12 2000-07-11 Kabushiki Kaisha Hayashibara Seibutsu Kagaku Kenkyujo Interleukin-18 (IL-18) receptor polypeptides and their uses
CN1269722A (zh) 1997-03-18 2000-10-11 Basf公司 调节对皮质类固醇反应的方法及组合物
AU8555698A (en) 1997-08-01 1999-02-22 Genset 5' ests for secreted proteins expressed in various tissues
DE69842099D1 (de) 1997-08-01 2011-02-24 Merck Serono Biodevelopment 5' ESTs für sekretierte Proteine, die in verschiedenen Geweben exprimiert werden
IL121860A0 (en) * 1997-08-14 1998-02-22 Yeda Res & Dev Interleukin-18 binding proteins their preparation and use
DK1075281T3 (da) 1998-04-28 2005-01-03 Applied Research Systems Polyol-IFN-beta-konjugater
CA2276216A1 (en) 1998-06-24 1999-12-24 Kabushiki Kaisha Hayashibara Seibutsu Kagaku Kenkyujo An artificial peptide capable of neutralizing the biological activity of interleukin-18
WO2000012555A1 (en) 1998-09-01 2000-03-09 Kabushiki Kaisha Hayashibara Seibutsu Kagaku Kenkyujo Interleukin 18-binding protein
AR022952A1 (es) 1999-03-19 2002-09-04 Smithkline Beecham Corp ANTICUERPO MONOCLONAL DE ROEDOR ESPECIFICAMENTE NEUTRALIZANTE PARA LA INTERLEUQUINA-18 HUMANA , UN FRAGMENTO FAB NEUTRALIZANTE o FRAGMENTO F(AB')2, UNA REGION DE COMPLEMENTARIEDAD DE CADENA LIGERA DE INMONOGLOBULINA(CDR), UNA MOLECULA DE ACIDO NUCLEICO, COMPOSICION FARMACEUTICA QUE LO COMPRENDE, EL
AU6078500A (en) 1999-07-09 2001-01-30 Amgen, Inc. Combination therapy for conditions leading to bone loss
WO2001019373A2 (en) 1999-09-17 2001-03-22 Basf Aktiengesellschaft Methods and compositions for modulating responsiveness to corticosteroids

Also Published As

Publication number Publication date
EA200000216A1 (ru) 2000-08-28
ES2149149T1 (es) 2000-11-01
IL121860A0 (en) 1998-02-22
CZ300818B6 (cs) 2009-08-19
US7101689B2 (en) 2006-09-05
PL338647A1 (en) 2000-11-06
KR20010022900A (ko) 2001-03-26
NO20000700L (no) 2000-04-14
CN1243021C (zh) 2006-02-22
NZ502392A (en) 2002-12-20
EA003675B1 (ru) 2003-08-28
AU755794B2 (en) 2002-12-19
CA2298855C (en) 2014-05-27
JP2001514876A (ja) 2001-09-18
US7799541B2 (en) 2010-09-21
AU8746098A (en) 1999-03-08
HUP0003533A2 (hu) 2001-01-29
BG65519B1 (bg) 2008-10-31
IL134523A (en) 2011-09-27
CA2298855A1 (en) 1999-02-25
JP4272348B2 (ja) 2009-06-03
PT1003781E (pt) 2009-10-26
IL122134A0 (en) 1998-04-05
BRPI9811940B8 (pt) 2021-07-06
ES2149149T3 (es) 2009-12-01
SK287194B6 (sk) 2010-03-08
AR013422A1 (es) 2000-12-27
US8436148B2 (en) 2013-05-07
HK1028773A1 (en) 2001-03-02
IL125463A0 (en) 1999-03-12
BRPI9811940A (pt) 2000-09-05
EP1003781B1 (en) 2009-09-23
WO1999009063A1 (en) 1999-02-25
DE1003781T1 (de) 2001-01-11
EE200000073A (en:Method) 2000-10-16
NO327240B1 (no) 2009-05-18
US6605280B1 (en) 2003-08-12
BRPI9811940B1 (pt) 2011-10-04
US20100010200A1 (en) 2010-01-14
US20040037829A1 (en) 2004-02-26
EP1003781A1 (en) 2000-05-31
HU226698B1 (en) 2009-07-28
DE69841175D1 (de) 2009-11-05
NO20000700D0 (no) 2000-02-11
EE05538B1 (et) 2012-04-16
KR100687388B1 (ko) 2007-02-26
PL206070B1 (pl) 2010-06-30
CY1109664T1 (el) 2014-08-13
DK1003781T3 (da) 2010-01-25
US20060154294A1 (en) 2006-07-13
SI1003781T1 (sl) 2009-12-31
IL134523A0 (en) 2001-04-30
SK1762000A3 (en) 2000-09-12
CZ2000490A3 (cs) 2000-08-16
BG104149A (bg) 2000-08-31
AR062867A2 (es) 2008-12-10
UA75862C2 (uk) 2006-06-15
CN1267307A (zh) 2000-09-20
HUP0003533A3 (en) 2003-08-28

Similar Documents

Publication Publication Date Title
ATE443719T1 (de) Interleukin-18 bindende proteine, deren herstellung und verwendung
ATE239693T1 (de) 3,3-diarylpropylamine , ihre verwendung und herstellung
DE69604285D1 (de) Polysiloxan-polyol makromere, deren herstellung und verwendung
DE69903464D1 (de) Haftverschlüsse, deren herstellung und sie aufweisenden produkten
DE69529026D1 (de) Trehalose, ihre Herstellung und ihre Verwendung
DE59709806D1 (de) Cycloolefincopolymere, ihre verwendung und daraus hergestellte formkörper
DE69927268D1 (de) Spezifische antikörper enthaltende bindungsproteine die das nekrotische tumorzentrum binden und deren verwendung
ATE258549T1 (de) Oxazolidindion-derivate, ihre herstellung und verwendung
DE69525676D1 (de) Polyurethan-Zusammensetzungen, ihre Herstellung und Verwendung
ATE430734T1 (de) Isochinoline und deren herstellung
EP1110969A4 (en) INTERLEUKIN 18-BINDING PROTEINS
ATE302604T1 (de) Thienylazolylalkoxyethanamine, deren herstellung und deren verwendung als medikamente
DE69625857D1 (de) Siliconderivate, ihre Herstellung und Verwendung
ATE335000T1 (de) Disulfid-vernetzte glycoprotein-hormone, ihre herstellung und verwendung
DE59800590D1 (de) Polymere organosiliciumverbindungen, deren herstellung und verwendung
ATE242770T1 (de) Neue alpha-hydroxysäurederivate, ihre herstellung und verwendung
EP0875567A3 (de) Myc-bindende Zinkfinger-Proteine, ihre Herstellung und ihre Verwendung
DE69521595D1 (de) Optisch-aktives Benzothiepin-Derivate, ihre Herstellung und Verwendung
DE69810521D1 (de) Abbeizzusammensetzungen, ihre Herstellung und Verwendung
ATE353367T1 (de) Group b streptococcus proteine und deren verwendung
DE59802922D1 (de) 3-substituierte tetrahydropyridopyrimidinon-derivate, ihre herstellung und verwendung
ATE268760T1 (de) Neue carbonsäurederivate, ihre herstellung und verwendung
ITMI941469A0 (it) Proteine ad attivita' antitumorale
DE69723463D1 (de) Cyclische organoselenderivate, ihre herstellung und verwendung
EP1073458A4 (en) CHLAMYDIA PROTEINS AND USES THEREOF

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1003781

Country of ref document: EP